New Rochelle, NY, Jan. 17, 2018--In the 10th anniversary year since a bone marrow stem cell transplant cured Timothy Ray Brown of his HIV infection, despite disappointment over decreasing public desire to find a cure for HIV, Timothy Ray Brown remains optimistic that the scientific and medical communities can and will achieve this if properly funded. He describes his most recent activities and the basis for his pessimism and optimism in the article "Timothy Ray Brown's Continuing Activism Toward Curing HIV," published in the latest HIV Cure Research Issue of AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the AIDS Research and Human Retroviruses website.
Throughout his "10 Cure Birthday" year's busy schedule of activities, Timothy Ray Brown "learned a few things last year that I found disappointing...I participated in two HIV cure seminars...The responses from many [participants] surprised me. Perhaps I misinterpreted this but I would say most of them indicated that they were afraid of HIV being cured. This is mostly due to the fear of how it would worsen their lives, that they would stand to lose all or most of the benefits they have today."
"The development of drugs to treat HIV infection has saved countless lives but led to complacency about this horrible virus," says Thomas Hope, PhD, Editor-in-Chief of AIDS Research and Human Retroviruses and Professor of Cell and Molecular Biology at Northwestern University, Feinberg School of Medicine (Chicago, IL). "In this update of his travels as an advocate of HIV cure research, Timothy Ray Brown reminds us that we still need to advocate for funding and educate the public about the important impact that a functional cure for HIV would have on society while understanding the complex ways that a cure would impact people living with AIDS. His insights as the first person cured of HIV are fascinating."
About the Journal
AIDS Research and Human Retroviruses, published monthly online with open access options and in print, presents papers, reviews, and case studies documenting the latest developments and research advances in the molecular biology of HIV and SIV and innovative approaches to HIV vaccine and therapeutic drug research, including the development of antiretroviral agents and immune-restorative therapies. Content also explores the molecular and cellular basis of HIV pathogenesis and HIV/HTLV epidemiology. The Journal features rapid publication of emerging sequence information, reports on clinical trials of emerging HIV therapies, and images in HIV research. Tables of content and a sample issue may be viewed on the AIDS Research and Human Retroviruses website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including AIDS Patient Care and STDs, Viral Immunology, and Journal of Interferon and Cytokine Research. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.